NLRP3 and gout: These decreases in arthritic severity and inflammatory cell infiltration were almost completely reversed by the intra-articular injection of recombinant IL-1β into the affected joints (Fig. 5K and Fig. S14), demonstrating the decisive role of the myeloid NCOA6–IL-1β axis in NLRP3-dependent gouty arthritis.